Calcium Channels Blockers and Progression of Kidney Disease

Ziakka, Stavroula; Kaperonis, Nikolaos; Ferentinou, Eleftheria; Karakasis, Filippos; Ntatsis, George; Kourvelou, Christine; Papagalanis, Nikolaos

doi:10.1080/08860220701643559

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical and experimental data have indicated renoprotective differences among the classes of CCBs [11][12][13]. Amlodipine inhibits the slow L-type voltage-gated calcium channels, with slow absorption (T max = 6 h) and longer half-life (t 1/2 = 30-60 h) [14].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records

Jadhav

Mohanan²,

Abraham³

et al. 2021

Cardiol Ther

View full text Add to dashboard Cite

Introduction: The renoprotective effects of dihydropyridine calcium channel blockers (CCBs) have been established as non-inferior to other classes of antihypertensive drugs. Studying their effect on renal outcome parameters, specifically for amlodipine as monotherapy, in real-world settings can further help in expanding its usage among Indian patients. This study was performed to assess the effects of amlodipine and other dihydropyridine CCBs (cilnidipine, benidipine and azelnidipine) on renal parameters and effectiveness in blood pressure reduction in Indian patients. Methods: The retrospective data of adult patients ([ 18 years) with essential hypertensive who were prescribed amlodipine (n = 92), cil-Supplementary Information The online version contains supplementary material available at

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records

Jadhav

Mohanan²,

Abraham³

et al. 2021

Cardiol Ther

View full text Add to dashboard Cite

show abstract

“…Of these 22 studies, 14 studies were excluded for the following reasons: duplicate data in 4 studies; there were 3 studies concerning renal outcomes but no ESRD or all-cause mortality [12][13][14] ; two studies were not randomized controlled trials 15,16 ; all the participants in two studies were hemodialysis patients 17,18 ; one study was about the survival only in kidney transplant patients 19 ; the number of participants in two trials was less than 100 20,21 ; Totally, eight studies were therefore included in this meta-analysis.…”

Section: Study Selectionmentioning

confidence: 99%

Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis

Zhao

Liu³

et al. 2016

Renal Failure

View full text Add to dashboard Cite

(2016) Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis, Renal Failure, 38:6,[849][850][851][852][853][854][855][856] Background:The renoprotective effect of inhibitors of renin-angiotensin system (RAS) has been identified through placebo-controlled trials. However, the effect of calcium-channel blockers (CCBs) on renal system is still controversial. Our current meta-analysis includes available evidences to compare the effect of dihydropyridine CCBs and ACEIs or ARBs on renal outcomes and mortality. We also further investigate whether CCBs can be used in combination with inhibitors of RAS to improve the prognosis of patients with chronic kidney disease (CKD). Methods and results: Electronic databases were searched up to July 2012, for clinical randomized controlled trials, assessing the effect of dihydropyridine CCBs on the incidence of end-stage renal disease (ESRD) and all-cause mortality in contrast to ACEIs or ARBs. Eight clinical trials were included containing 25,647 participants. ESRD showed significantly higher frequency with CCBs therapy compared with ACEIs or ARBs therapy, though blood pressure was decreased similarly in both groups in every trial (OR, 1.25; 95% CI, 1.05-1.48; p ¼ 0.01). In contrast, there was no significant difference in the incidence of all-cause mortality between these two groups, though ACEIs or ARBs exhibited better renoprotective effect compared to CCBs (OR, 0.96; 95% CI, 0.89-1.03; p ¼ 0.24). Conclusions: CCBs did not increase all-cause mortality incidence in patients with CKD though they displayed weaker renoprotective, compared to ACEIs or ARBs therapy. Our results suggest the combination of a CCB and an ACEI or ARB should be a preferable antihypertensive therapy in patients with CKD, considering their higher effect in decreasing blood pressure and fewer adverse metabolic problems caused.

show abstract

Dihydropyridine calcium channel blockers and renal disease

Robles

Fıcı

2016

Hypertens Res

View full text Add to dashboard Cite

Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation. Some evidence has accumulated in recent years demonstrating that the new dihydropyridinic CCBs (such as lercanidipine or efonidipine) may affect both postglomerular and preglomerular vessels, resulting in a decreased filtration fraction and nephroprotective effect. Increasing clinical and experimental evidence supports this view and the use of CCBs in CKD hypertensive patients.

show abstract

Calcium Channels Blockers and Progression of Kidney Disease

Cited by 4 publications

References 30 publications

Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records

Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records

Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis

Dihydropyridine calcium channel blockers and renal disease

Contact Info

Product

Resources

About